ArticleCEN case reports2026
Experience with early treatment using febuxostat in a patient with adenine phosphoribosyltransferase deficiency after pediatric kidney transplantation: a case report.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplantation (KT) for adenine phosphoribosyltransferase (APRT) deficiency is performed using the xanthine dehydrogenase (XDH) inhibitor allopurinol to prevent the recurrence of dihydroxyadenine (DHA) nephropathy. However, there are few reports on the use of febuxostat after pediatric KT for APRT deficiency. Herein, we report the case of a 12-year-old boy with congenital kidney and urinary tract abnormalities who underwent deceased-donor KT for end-stage kidney disease caused by APRT deficiency. The patient developed acute kidney injury during infancy due to urinary tract stones and was diagnosed with APRT deficiency based on stone analysis and genetic testing. Treatment with allopurinol was initiated. However, the patient had persistent renal dysfunction and required peritoneal dialysis at the age of 9 years. Grade IV left vesicoureteral reflux (VUR) and a large bladder diverticulum were observed. Although the VUR resolved, the patient underwent bladder diverticulectomy and ureteroneocystostomy before KT due to recurrent complicated urinary tract infections associated with an enlarged bladder diverticulum and residual urine. Subsequently, the patient underwent KT, and the XDH inhibitor was switched from allopurinol to febuxostat. Transplant renal biopsy at 4 months post-KT showed no recurrence of DHA nephropathy; graft function remained stable. This case demonstrated that pediatric patients with APRT deficiency undergoing KT could be successfully managed with febuxostat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.